Showing results (181-190 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|March 15, 2026
Histoplasmosis: a missing piece in the global efforts to end HIV deathsAlessandro C Pasqualotto, Thuy Le, Tarsila Vieceli, et al.
The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The Lancet. HIV|April 2, 2026
The vaginal microbiome and HIV acquisition riskLindi Masson, Nina Radzey, Andrea G Abrahams, et al.
The Lancet. HIV|April 5, 2026
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysisTriin Umbleja, Mohammad U Zafar, Sara McCallum, et al.
The Lancet. HIV|March 19, 2026
Service needs of people living with HIV in the UK (Positive Voices 2022): a cross-sectional surveyAnne Williamson, Fiona C Lampe, Adamma Aghaizu, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
The Lancet. HIV|June 10, 2026
National and regional analysis of HIV transmission dynamics in Morocco: a mathematical modelling studyHiam Chemaitelly, Ibtissam Khoudri, Amina El Kettani, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|August 27, 2016
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 studyKathleen Squires, Cissy Kityo, Sally Hodder, et al.
The Lancet. HIV|August 7, 2023
Metabolic implications and safety of dolutegravir use in pregnancyValeriya Dontsova, Haneesha Mohan, Camille Blanco, et al.
Pageof 79